Powered by Open Innovation: Opportunities and Challenges in the Pharma Sector
Powered by Open Innovation: Opportunities and Challenges in the Pharma Sector
复制标题
DOI：
10.1007/s40290-019-00280-5
复制
发表时间：
2019-06-01
影响因子：
2.5
通讯作者：
Alvim-Gaston, Maria
中科院分区：
文献类型：
--
作者：
Angeles Martinez-Grau, Maria;Alvim-Gaston, Maria
医药创新的价值是显而易见的。尽管在21世纪取得了所有进展，但仍有许多未得到满足的医疗需求和改善保健的机会。制药公司面临的挑战包括如何在知识不断增长和技术日益尖端的环境中保持竞争力和灵活性，以及如何产生足够的收入来维持自身的增长。为此，制药公司被迫适应不同的商业模式，以应对新的挑战。该行业受到研发(R&D)周期长和创新治疗成功率低的困扰；必须做出一些改变。必须在发现、开发、制造和商业化过程中进行外部协作。此外，合作的频率和范围有所增加，扩大了在学术界、研究机构和生物技术公司接触全球科学人才的机会。尽管人们认为制药公司是封闭的或受到严格控制的行业，但开放式创新已经在制药行业得到了很好的确立，并被用来补充研发，以更快、更低的成本为患者带来新药。多年来，每家制药公司都定制了开放创新的概念，以根据特定的需求和产品开发自己的模式。独立于这种模式，在外部创新中建立成功的伙伴关系需要超越传统组织边界的接触和联系。实施开放创新战略需要进行重大的内部文化变革，这些战略应该共存，而不是与传统的运营方式竞争。重大变化给科学家和组织带来了挑战，但也创造了多重机遇。高质量的药物发现需要持续学习和开放的思维方式，采用新的操作模式，并实施高效的合作。
The value of innovation in medicines is clear. Despite all of the progress in the twenty-first century, there are still many unmet medical needs and opportunities to improve healthcare. The challenges for pharmaceutical companies include ways in which to stay competitive and flexible in an environment of constant knowledge growth and increasingly sophisticated technologies, and ways to generate sufficient revenues to sustain their own growth. To that end, pharmaceutical companies are compelled to adapt different business models in the face of new challenges. The industry is plagued with long research and development (R&D) cycles and low success rates for innovative treatments; something has to change. The need to collaborate externally across the process of discovery, development, manufacturing and commercialization is a must. Furthermore, collaborations have increased in frequency and scope, expanding the opportunities to access global scientific talent in academia, research institutes and biotechnology companies. Despite the perception that pharma companies are closed' or tightly controlled industries, open innovation is already well established in the pharmaceutical sector and used to supplement R&D in the process of bringing new medicines for patients faster, and at a lower cost. Over the years, each pharma company has tailored the open-innovation concept to develop its own model based on particular needs and offerings. Independently of the model, the creation of successful partnerships in external innovation requires reaching out and connecting beyond the traditional organizational boundaries. Substantial internal cultural changes are required to implement open-innovation strategies that should co-exist without competing with the traditional ways of operating. Major changes bring challenges but create multiple opportunities for scientists and organizations. High-quality drug discovery requires continuous learning and an open way of thinking to adopt novel operational models and to implement efficient collaborations.